New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
Published on
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Published on
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Published on
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Published on
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
Published on
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
Published on
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
Published on
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Published on
Trials of more game-changing cell therapies for pediatric cancer and other diseases are underway or on the horizon at Children's Hospital of Philadelphia.
Published on
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
Published on
CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.
Published on
Children’s Hospital of Philadelphia was recognized specifically for significant contributions to the development of a new treatment for a certain pediatric leukemia.